Pfizer FY2026 Earnings Forecast Raised by Erste Group Bank

Pfizer Inc. (NYSE:PFE) – Research analysts at Erste Group Bank boosted their FY2026 earnings per share (EPS) estimates for shares of Pfizer in a research note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings of $2.97 per share for the year, up from their prior forecast of $2.96. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. Scotiabank boosted their price target on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Cantor Fitzgerald upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.72.

Pfizer Trading Up 0.4%

NYSE PFE opened at $28.39 on Tuesday. The company has a market cap of $161.82 billion, a price-to-earnings ratio of 37.36, a P/E/G ratio of 1.91 and a beta of 0.32. Pfizer has a 52 week low of $23.62 and a 52 week high of $29.21. The business has a 50 day moving average price of $27.75 and a 200-day moving average price of $26.51. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is presently 226.32%.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. State Street Corp increased its stake in Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Pfizer by 11.1% in the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock valued at $1,512,948,000 after buying an additional 5,364,929 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Pfizer during the 2nd quarter worth approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Pfizer by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after buying an additional 293,029 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.